- Home
- LII vs RPRX Comparison
LII vs RPRX Comparison
Compare LII & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LII | RPRX |
|---|---|---|
| Founded | 1895 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 16.7B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LII | RPRX |
|---|---|---|
| Price | $538.97 | $43.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $595.92 | $47.75 |
| AVG Volume (30 Days) | 547.5K | ★ 4.0M |
| Earning Date | 01-28-2026 | 02-11-2026 |
| Dividend Yield | 0.98% | ★ 2.13% |
| EPS Growth | ★ 1.11 | N/A |
| EPS | ★ 22.79 | 1.75 |
| Revenue | ★ $5,195,300,000.00 | $2,349,844,000.00 |
| Revenue This Year | $6.89 | $38.81 |
| Revenue Next Year | $5.26 | $2.26 |
| P/E Ratio | ★ $23.22 | $25.15 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $443.19 | $29.66 |
| 52 Week High | $689.44 | $44.93 |
Technical Indicators
Market Signals| Indicator | LII | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 68.43 |
| Support Level | $520.39 | $40.16 |
| Resistance Level | $541.34 | $44.93 |
| Average True Range (ATR) | 17.60 | 0.70 |
| MACD | 3.18 | 0.30 |
| Stochastic Oscillator | 99.49 | 76.44 |
Price Performance
Historical ComparisonAbout LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.